Immuneering Corp
IMRX
Company Profile
Business description
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Contact
245 Main Street
Second Floor
CambridgeMA02142
USAT: +1 617 500-8080
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
57
Stocks News & Analysis
stocks
ASX iron ore player downgraded ahead of earnings
Rising costs and delayed production drive fair value cut for ASX iron ore player.
stocks
Global tensions drive profitability for ASX energy provider
Supply disruptions turbocharge refining profits and lift earnings forecasts for ASX energy share.
stocks
ASX energy share undervalued ahead of earnings
Pricing strength outweighs temporary production headwinds.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,405.40 | 59.70 | 0.64% |
| CAC 40 | 8,669.30 | 0.00 | 0.00% |
| DAX 40 | 26,126.30 | 76.05 | -0.29% |
| Dow JONES (US) | 54,349.12 | 263.24 | 0.49% |
| FTSE 100 | 10,888.30 | 8.92 | 0.08% |
| HKSE | 25,915.82 | 62.90 | 0.24% |
| NASDAQ | 26,363.44 | 221.55 | -0.83% |
| Nikkei 225 | 66,300.44 | 2,342.91 | 3.66% |
| NZX 50 Index | 13,951.64 | 45.54 | -0.33% |
| S&P 500 | 7,723.55 | 12.97 | -0.17% |
| S&P/ASX 200 | 9,227.80 | 51.30 | 0.56% |
| SSE Composite Index | 3,878.43 | 56.15 | 1.47% |